Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial

This publication has 23 references indexed in Scilit:

• Conventional-Dose Chemotherapy Compared with High-Dose Chemotherapy plus Autologous Hematopoietic Stem-Cell Transplantation for Metastatic Breast Cancer
  New England Journal of Medicine, 2000
• Where next with stem-cell-supported high-dose therapy for breast cancer?
  The Lancet, 2000
• Randomized Trial of High-Dose Chemotherapy and Blood Cell Autografts for High-Risk Primary Breast Carcinoma
  JNCI Journal of the National Cancer Institute, 2000
• Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF
  British Journal of Cancer, 1999
• Dose–response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer
  European Journal Of Cancer, 1998
• Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement
  The Lancet, 1998
• Conventional Compared with Individualized Chemotherapy for Childhood Acute Lymphoblastic Leukemia
  New England Journal of Medicine, 1998
• Tailored Chemotherapy to Equal Toxicity: Is It Possible?
  Published by Springer Nature ,1998
• Comprehensive Criteria for Assessing Therapy-Induced Toxicity
  Cancer Investigation, 1989
• Clinical Pharmacokinetics-Pharmacodynamicsof Anticancer Drugs
  Clinical Pharmacokinetics, 1989